Immuneering (NASDAQ:IMRX) Given New $18.00 Price Target at Needham & Company LLC

Immuneering (NASDAQ:IMRX) had its price objective raised by equities research analysts at Needham & Company LLC from $11.00 to $18.00 in a report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 287.93% from the stock’s current price.

IMRX has been the subject of a number of other research reports. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Immuneering in a research report on Tuesday, May 19th. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a research note on Monday. Oppenheimer restated an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald assumed coverage on Immuneering in a report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.57.

Immuneering Stock Performance

Shares of IMRX opened at $4.64 on Monday. The company’s 50-day moving average price is $4.83 and its 200 day moving average price is $5.12. Immuneering has a 12-month low of $2.90 and a 12-month high of $10.08. The firm has a market cap of $300.21 million, a P/E ratio of -3.97 and a beta of 0.41.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.09. Equities research analysts forecast that Immuneering will post -1.09 earnings per share for the current year.

Hedge Funds Weigh In On Immuneering

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Empery Asset Management LP acquired a new stake in shares of Immuneering in the fourth quarter valued at $17,601,000. Vanguard Group Inc. grew its stake in Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after purchasing an additional 1,358,322 shares in the last quarter. State Street Corp increased its holdings in Immuneering by 1,289.7% during the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock worth $15,807,000 after purchasing an additional 2,229,374 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Immuneering by 10.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company’s stock worth $13,121,000 after purchasing an additional 195,176 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in Immuneering in the 3rd quarter valued at about $6,602,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.